6533b833fe1ef96bd129ba3a

RESEARCH PRODUCT

Basal growth hormone concentrations in blood and the risk for prostate cancer: A case-control study

Maddalena BarbaMaddalena BarbaTeresa QuattrinHolger J. SchünemannGiuseppe CarrubaPaola MutiRuben CartagenaBarbara J. FuhrmanThelma C. HurdThelma C. Hurd

subject

Malemedicine.medical_specialtyWaistUrologyPopulationGastroenterologyProstate cancerBasal (phylogenetics)Risk FactorsInternal medicineBiomarkers TumormedicineHumansInsulin-Like Growth Factor IRisk factoreducationAgedAged 80 and overeducation.field_of_studybusiness.industryConfoundingCase-control studyProstatic NeoplasmsMiddle Agedmedicine.diseaseGrowth hormone secretionEndocrinologyOncologyCase-Control StudiesGrowth Hormonebusiness

description

OBJECTIVE To assess the relationship between basal serum growth hormone (GH) levels and prostate cancer risk. METHODS We conducted a population-based case-control study; cases included 68 men, aged 45–85 years, diagnosed with incident, primary, histologically confirmed, and clinically apparent (stage B and higher) prostate cancer. Controls included 240 men, frequency matched on age and residential area. Age, race, BMI, waist circumference, history of enlarged prostate, education, and current smoking status, were all considered as possible confounders. RESULTS We found a statistically significant trend of decreasing prostate cancer risk across increasing GH quintiles, in both crude (OR: 0.31, 95% CI: 0.12–0.83, P for trend 0.01) and adjusted models (OR: 0.35, 95% CI: 0.12–1.05, P for trend 0.03), in the highest compared to the lowest quintile, respectively. CONCLUSIONS Lower basal levels of GH in serum are associated with increased prostate cancer risk. The inverse association may be explained by the negative feedback loop generated by IGF-1 produced by the tumor on GH secretion. © 2005 Wiley-Liss, Inc.

yearjournalcountryeditionlanguage
2005-01-25The Prostate
https://doi.org/10.1002/pros.20203